X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4765) 4765
Book Review (1219) 1219
Publication (495) 495
Book Chapter (28) 28
Conference Proceeding (17) 17
Dissertation (7) 7
Magazine Article (4) 4
Newspaper Article (4) 4
Book / eBook (3) 3
Government Document (3) 3
Reference (3) 3
Presentation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3727) 3727
trastuzumab (3715) 3715
humans (3491) 3491
oncology (2782) 2782
female (2678) 2678
breast cancer (2472) 2472
breast neoplasms - drug therapy (1834) 1834
cancer (1434) 1434
breast neoplasms - pathology (1246) 1246
receptor, erbb-2 - metabolism (1223) 1223
her2 (1217) 1217
chemotherapy (1172) 1172
antineoplastic agents - therapeutic use (967) 967
breast neoplasms - metabolism (965) 965
animals (935) 935
cell line, tumor (927) 927
antibodies, monoclonal, humanized (885) 885
middle aged (825) 825
breast neoplasms - genetics (806) 806
therapy (806) 806
skin and connective tissue diseases (782) 782
care and treatment (746) 746
resistance (723) 723
metastasis (701) 701
receptor, erbb-2 - genetics (693) 693
aged (684) 684
adult (679) 679
monoclonal-antibody (642) 642
antineoplastic agents - pharmacology (639) 639
research (628) 628
expression (618) 618
trastuzumab resistance (616) 616
tumors (601) 601
epidermal growth factor (584) 584
antibodies, monoclonal - therapeutic use (582) 582
antineoplastic combined chemotherapy protocols - therapeutic use (575) 575
treatment outcome (573) 573
receptor, erbb-2 - antagonists & inhibitors (572) 572
mice (569) 569
lapatinib (560) 560
medicine & public health (545) 545
prognosis (542) 542
drug resistance, neoplasm (540) 540
adjuvant chemotherapy (537) 537
breast-cancer (513) 513
analysis (498) 498
erbb-2 protein (482) 482
health aspects (467) 467
survival (453) 453
drug therapy (443) 443
cancer therapies (440) 440
growth-factor receptor (438) 438
neoplasms (426) 426
cell biology (419) 419
immunohistochemistry (403) 403
signal transduction (395) 395
gene expression (390) 390
pharmacology & pharmacy (390) 390
metastatic breast-cancer (369) 369
receptor (369) 369
kinases (367) 367
activation (366) 366
genetic aspects (365) 365
growth (365) 365
antibodies, monoclonal - pharmacology (360) 360
antineoplastic agents (351) 351
cells (348) 348
proteins (338) 338
antibodies, monoclonal, humanized - therapeutic use (334) 334
apoptosis (332) 332
phase-ii (330) 330
article (328) 328
gene amplification (324) 324
antimitotic agents (323) 323
open-label (316) 316
disease-free survival (312) 312
mutation (312) 312
monoclonal antibodies (311) 311
signal transduction - drug effects (308) 308
pertuzumab (307) 307
hematology, oncology and palliative medicine (305) 305
cell proliferation - drug effects (304) 304
development and progression (304) 304
neoplasm metastasis (298) 298
phase-ii trial (296) 296
breast neoplasms - mortality (295) 295
cancer research (292) 292
drug resistance (288) 288
xenograft model antitumor assays (281) 281
biochemistry & molecular biology (280) 280
phosphorylation (280) 280
herceptin (274) 274
clinical trials (268) 268
male (263) 263
efficacy (261) 261
paclitaxel (260) 260
patients (257) 257
erbb2 (255) 255
antibodies, monoclonal, humanized - pharmacology (253) 253
gene expression regulation, neoplastic (252) 252
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4690) 4690
French (51) 51
Japanese (23) 23
German (10) 10
Chinese (9) 9
Polish (5) 5
Hungarian (3) 3
Spanish (3) 3
Slovak (2) 2
Bosnian (1) 1
Czech (1) 1
Italian (1) 1
Korean (1) 1
Persian (1) 1
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 3/2011, Volume 108, Issue 9, pp. 3761 - 3766
Journal Article
Journal Article
Journal Article
Breast Cancer Research, ISSN 1465-5411, 11/2011, Volume 13, Issue 6, pp. R121 - R121
Journal Article
International Journal of Cancer, ISSN 0020-7136, 09/2014, Volume 135, Issue 6, pp. 1356 - 1368
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2009, Volume 15, Issue 24, pp. 7479 - 7491
HER2 is a transmembrane oncoprotein encoded by the HER2/ neu gene and is overexpressed in approximately 20 to 25% of invasive breast cancers. It can be... 
SIGNAL-TRANSDUCTION | ADJUVANT CHEMOTHERAPY | RECEPTOR TYROSINE KINASES | PREOPERATIVE TRASTUZUMAB | ONCOLOGY | FC-GAMMA-R | EPIDERMAL-GROWTH-FACTOR | IN-VIVO | MONOCLONAL-ANTIBODY | PHOSPHOINOSITIDE 3-KINASE | METASTATIC BREAST
Journal Article
Journal Article
Molecular Cell, ISSN 1097-2765, 08/2012, Volume 47, Issue 4, pp. 570 - 584
Journal Article
Cancer Research, ISSN 0008-5472, 06/2017, Volume 77, Issue 12, pp. 3280 - 3292
Journal Article
Oncogene, ISSN 0950-9232, 06/2014, Volume 33, Issue 25, pp. 3334 - 3341
Human epidermal growth factor receptor 2 (HER2)-directed treatment using trastuzumab has shown clinical benefit in HER2-positive gastric cancer. Clinical... 
lapatinib resistance | HER2-positive gastric cancer | β-catenin | epithelial-mesenchymal transition | XAV939 | Testican-1 | b-catenin | beta-catenin | BIOCHEMISTRY & MOLECULAR BIOLOGY | RECEPTOR | CELL-LINES | TRASTUZUMAB RESISTANCE | GEFITINIB RESISTANCE | CELL BIOLOGY | BREAST-CANCER | LUNG-CANCER | ONCOLOGY | GROWTH | GENETICS & HEREDITY | TYROSINE KINASE INHIBITOR | HER2 | EXPRESSION | Proto-Oncogene Proteins c-met - metabolism | Transcription, Genetic - drug effects | Receptor, ErbB-2 - genetics | Humans | Receptor, ErbB-2 - metabolism | Stomach Neoplasms - metabolism | Drug Resistance, Neoplasm | Epithelial-Mesenchymal Transition - drug effects | G1 Phase - drug effects | Epithelial-Mesenchymal Transition - genetics | Cell Cycle Checkpoints - genetics | G1 Phase - genetics | Stomach Neoplasms - genetics | Proteoglycans - metabolism | Signal Transduction - genetics | Stomach Neoplasms - drug therapy | beta Catenin - metabolism | beta Catenin - genetics | Proto-Oncogene Proteins c-met - genetics | Up-Regulation - drug effects | Signal Transduction - drug effects | Cell Cycle Checkpoints - drug effects | Cell Line, Tumor | Quinazolines - pharmacology | Proteoglycans - genetics | Oncology, Experimental | Genetic research | Genetic aspects | Research | Properties | Drug resistance | Growth factors | Stomach cancer | Cancer | Signal transduction | Chemotherapy | Epidermal growth factor | Gene expression | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2017, Volume 23, Issue 3, pp. 636 - 648
Purpose: Although trastuzumab administration improved the outcome of HER2-positive breast cancer patients, resistance events hamper its clinical benefits. We... 
TUMOR-INFILTRATING LYMPHOCYTES | KAPPA-B ACTIVATION | ONCOLOGY | GROWTH | ACQUIRED-RESISTANCE | HER2 RECEPTOR | ANTIBODY | NECROSIS-FACTOR-ALPHA | CHRONIC INFLAMMATION | UP-REGULATION | CELL-LINE | Humans | Tumor Necrosis Factor-alpha - genetics | Neoplasm Proteins - antagonists & inhibitors | Stomach Neoplasms - pathology | Maytansine - pharmacology | Recombinant Fusion Proteins - metabolism | Immunoconjugates - pharmacology | Mucin-4 - biosynthesis | RNA Interference | Tumor Necrosis Factor-alpha - immunology | Female | Receptor, ErbB-2 - antagonists & inhibitors | Trastuzumab - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Trastuzumab - metabolism | Trastuzumab - therapeutic use | Antibody-Dependent Cell Cytotoxicity | Maytansine - analogs & derivatives | Breast Neoplasms - drug therapy | Mucin-4 - genetics | Antineoplastic Agents, Immunological - metabolism | Antineoplastic Agents, Immunological - pharmacology | Drug Synergism | Up-Regulation - drug effects | Xenograft Model Antitumor Assays | Disease-Free Survival | Animals | Signal Transduction - drug effects | Antineoplastic Agents, Immunological - therapeutic use | Breast Neoplasms - pathology | Mice, Nude | Tumor Necrosis Factor-alpha - physiology | Cell Line, Tumor | Breast Neoplasms - mortality | Neoplasm Proteins - analysis | Mice | Receptor, ErbB-2 - analysis | Mucin-4 - physiology | Drug Resistance, Neoplasm - physiology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Drug Resistance, Neoplasm - drug effects | Binding | Immunohistochemistry | Immunoglobulins | Toxicity | Blocking antibodies | Antibodies | Cytotoxicity | Breast cancer | siRNA | Tumor cell lines | Tumor necrosis factor-α | Patients | ErbB-2 protein | Design engineering | Mucin | Experimental design | Cell lines | Biomarkers | Breast | Genetic engineering | Bioindicators | Trastuzumab | Tumors | Cancer | Index Medicus
Journal Article